Ukko is a brand with a clear mission: to improve the lives of millions suffering from food allergies and gluten-related disorders. With the increasing prevalence of these conditions and their significant impact on social, health, and economic levels, Ukko seeks to offer effective solutions. Currently, healthcare costs related to food allergies and disorders amount to a staggering $25 billion annually.

Notably, 1 in every 13 children in the United States is affected by food allergies, and cases of celiac disease have doubled every fifteen years. Ukko's approach involves utilizing their computational engineering platform to redesign food allergens, transforming them into safe and efficient therapeutics. By mapping the molecular structure of food allergies and gaining crucial insights into the biological mechanisms driving human-food interactions, Ukko creates new versions of proteins that do not trigger immune responses.

This breakthrough allows for a groundbreaking approach to treating protein-based allergies. With a founding team that includes experienced Co-Founders Anat Binur and Yanay Ofran, as well as an impressive lineup of advisors and investors, Ukko is well positioned to revolutionize the field of food allergy treatment. Stay informed about their journey and contact them to learn more about their innovative solutions